UNSPSC 51434925: Deserpidine/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434925 Deserpidine/hydrochlorothiazide is a Commodity code that does not reflect the pharmaceutical procurement activity currently appearing under it in state and local solicitations. The recent opportunities posted against this code involve emergency medications and generic pharmaceuticals broadly — advanced life support drugs for emergency medical services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals for statewide cooperative purchasing — rather than the specific antihypertensive combination named in the code itself. State and local buyers soliciting under this code include city fire departments and rescue services, state health and human services commissions, and multi-jurisdictional cooperative purchasing alliances administering statewide pharmaceutical contracts for participating government entities and facilities.

The geographic spread spans Florida, Texas, and Minnesota, with the most recent activity concentrated in cooperative purchasing mechanisms serving multiple states. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (due April 8, 2026, estimated contract value $40,000) requiring sealed bids for labetalol, epinephrine, adenosine, and diltiazem vials for use by Tampa Fire Rescue, with a one-year term and options to renew for two additional years plus three 30-day extensions, including a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 (response due April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awards effective July 1, 2026 and a two-year initial term.